カテゴリ： 世界, 医療/バイオ, Market Monitor Global

内因性ペプチド物質のグローバル市場展望 2023年-2029年：神経ペプチド、ホルモン、サイトカイン、ペプチドホルモン、生理活性ペプチド

■ 英語タイトル：Endogenous Peptide Substances Market, Global Outlook and Forecast 2023-2029

調査会社Market Monitor Global社が発行したリサーチレポート（データ管理コード：MMG23DC12333）■ 発行会社/調査会社：Market Monitor Global
■ 商品コード：MMG23DC12333
■ 発行日：2023年12月
■ 調査対象地域：グローバル、北米、アメリカ、ヨーロッパ、アジア、日本、中国、東南アジア、インド、南米、中東・アフリカなど
■ 産業分野：医療
■ ページ数：61
■ レポート言語：英語
■ レポート形式：PDF
■ 納品方式：Eメール（受注後2-3営業日）
■ 販売価格オプション（消費税別）
Single User（1名様閲覧用）USD3,250 ⇒換算￥494,000見積依頼/購入/質問フォーム
Multi User（20名様閲覧用）USD4,225 ⇒換算￥642,200見積依頼/購入/質問フォーム
Enterprise User（閲覧人数制限なし）USD4,875 ⇒換算￥741,000見積依頼/購入/質問フォーム
※販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額（日本円）＋消費税＋配送料（Eメール納品は無料）」です。
※Eメールによる納品の場合、通常ご注文当日～2日以内に納品致します。
※レポート納品後、納品日＋5日以内に請求書を発行・送付致します。（請求書発行日より2ヶ月以内の銀行振込条件、カード払いも可能）
※Market Monitor Global社の概要及び新刊レポートはこちらでご確認いただけます。
★グローバルリサーチ資料[内因性ペプチド物質のグローバル市場展望 2023年-2029年：神経ペプチド、ホルモン、サイトカイン、ペプチドホルモン、生理活性ペプチド]についてメールでお問い合わせはこちら
*** レポート概要（サマリー）***

当調査レポートは次の情報を含め、世界の内因性ペプチド物質市場規模と予測を収録しています。・世界の内因性ペプチド物質市場：売上、2018年-2023年、2024年-2029年
・世界の内因性ペプチド物質市場：販売量、2018年-2023年、2024年-2029年
・世界のトップ5企業、2022年

世界の内因性ペプチド物質市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「神経ペプチド」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。

内因性ペプチド物質のグローバル主要企業は、Assertio Therapeutics Inc.、 Cipher Pharmaceuticals Inc.、 Endo International Plc、 Biosynth Carbosynth、 Lannett Co. Inc.、 Pfizer、 Johnson & Johnson、 Peptide Institute、 Abbexa、 Phoenix Pharmaceuticals、 Creative Peptidesなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。

MARKET MONITOR GLOBAL（MMG）は、内因性ペプチド物質のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。

【セグメント別市場分析】

世界の内因性ペプチド物質市場：タイプ別、2018年-2023年、2024年-2029年
世界の内因性ペプチド物質市場：タイプ別市場シェア、2022年
・神経ペプチド、ホルモン、サイトカイン、ペプチドホルモン、生理活性ペプチド

世界の内因性ペプチド物質市場：用途別、2018年-2023年、2024年-2029年
世界の内因性ペプチド物質市場：用途別市場シェア、2022年
・研究、医療、その他

世界の内因性ペプチド物質市場：地域・国別、2018年-2023年、2024年-2029年
世界の内因性ペプチド物質市場：地域別市場シェア、2022年
・北米：アメリカ、カナダ、メキシコ
・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア
・アジア：中国、日本、韓国、東南アジア、インド
・南米：ブラジル、アルゼンチン
・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE

【競合分析】

また、当レポートは主要な市場参加者の分析を提供します。
・主要企業における内因性ペプチド物質のグローバル売上、2018年-2023年
・主要企業における内因性ペプチド物質のグローバル売上シェア、2022年
・主要企業における内因性ペプチド物質のグローバル販売量、2018年-2023年
・主要企業における内因性ペプチド物質のグローバル販売量シェア、2022年

さらに、当レポートは主要企業のプロファイルを提示します。
Assertio Therapeutics Inc.、 Cipher Pharmaceuticals Inc.、 Endo International Plc、 Biosynth Carbosynth、 Lannett Co. Inc.、 Pfizer、 Johnson & Johnson、 Peptide Institute、 Abbexa、 Phoenix Pharmaceuticals、 Creative Peptides

*************************************************************

・調査・分析レポートの概要
内因性ペプチド物質市場の定義
市場セグメント
世界の内因性ペプチド物質市場概要
当レポートの特徴・ベネフィット
調査手法と情報源

・世界の内因性ペプチド物質市場規模
世界の内因性ペプチド物質市場規模：2022年 VS 2029年
世界の内因性ペプチド物質市場規模と予測 2018年-2029年

・競争状況
グローバルトップ企業
売上ベースでのグローバルトップ企業
企業別グローバルでの内因性ペプチド物質の売上
グローバルトップ3およびトップ5企業、2022年売上ベース
グローバル企業の内因性ペプチド物質製品タイプ
グローバルにおけるティア1、ティア2、ティア3企業

・タイプ別市場分析
タイプ区分：神経ペプチド、ホルモン、サイトカイン、ペプチドホルモン、生理活性ペプチド
内因性ペプチド物質のタイプ別グローバル売上・予測

・用途別市場分析
用途区分：研究、医療、その他
内因性ペプチド物質の用途別グローバル売上・予測

・地域別市場分析
地域別内因性ペプチド物質市場規模 2022年と2029年
地域別内因性ペプチド物質売上・予測
北米市場：アメリカ、カナダ、メキシコ
ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア
アジア市場：中国、日本、韓国、東南アジア、インド
南米市場：ブラジル、アルゼンチン
中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE

・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど）
Assertio Therapeutics Inc.、 Cipher Pharmaceuticals Inc.、 Endo International Plc、 Biosynth Carbosynth、 Lannett Co. Inc.、 Pfizer、 Johnson & Johnson、 Peptide Institute、 Abbexa、 Phoenix Pharmaceuticals、 Creative Peptides
...

This research report provides a comprehensive analysis of the Endogenous Peptide Substances market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Endogenous Peptide Substances market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Endogenous Peptide Substances, challenges faced by the industry, and potential opportunities for market players.
The global Endogenous Peptide Substances market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Endogenous Peptide Substances market presents opportunities for various stakeholders, including Research, Medicine. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Endogenous Peptide Substances market. Additionally, the growing consumer demand present avenues for market expansion.
The global Endogenous Peptide Substances market was valued at US$ million in 2022 and is projected to reach US$ million by 2029, at a CAGR of % during the forecast period.
The driving force of endogenous peptides mainly comes from the following aspects:
Biological functions of bioactive peptides: Bioactive peptides have a variety of biological functions, such as neuromodulation, immune regulation, anti-inflammation, anti-tumor, etc. These functions play an important role in maintaining normal physiological functions and health of the human body. For example, endorphins have analgesic effects and can relieve pain, while growth hormone-releasing hormone can stimulate the secretion of growth hormone and regulate the growth and development of the human body. These functions enable endogenous peptides to play important physiological roles in the human body.
Demand for drug research and development: With the development of medical technology, people’s demand for drugs is getting higher and higher. As an important type of biological drugs, peptide drugs are receiving more and more attention in their research and development and application. Peptide drugs have many advantages, such as high efficiency, low toxicity, and good biocompatibility. Therefore, they are widely used in anti-tumor, anti-infection, neurological diseases and other fields. As an important source of peptide drugs, endogenous peptides have received more attention in their development and utilization.
Progress in production technology: Since the chemical structure and biological activity of endogenous peptides are strictly protected, special attention needs to be paid to maintaining their original biological activity during production and processing. With the continuous advancement of production technology, people have explored more efficient and safer preparation methods, which has greatly improved the production efficiency of endogenous peptides and reduced costs.
Expansion of indications: As the research and development of endogenous peptides continues to deepen, their indications are also expanding. For example, insulin is an important drug in the treatment of diabetes, while growth hormone is widely used in anti-aging and other fields. The expansion of these indications has led to an increasing demand for endogenous peptides.
Key Features:
The research report on the Endogenous Peptide Substances market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Endogenous Peptide Substances market.
Market Overview: The report provides a comprehensive overview of the Endogenous Peptide Substances market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Neuropeptides, Hormones), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Endogenous Peptide Substances market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Endogenous Peptide Substances market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Endogenous Peptide Substances market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Endogenous Peptide Substances market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Endogenous Peptide Substances market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Endogenous Peptide Substances market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Endogenous Peptide Substances, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Endogenous Peptide Substances market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Endogenous Peptide Substances market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Neuropeptides
Hormones
Cytokines
Peptide Hormones
Bioactive Peptides
Market segment by Application
Research
Medicine
Others
Global Endogenous Peptide Substances Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Assertio Therapeutics Inc.
Cipher Pharmaceuticals Inc.
Endo International Plc
Biosynth Carbosynth
Lannett Co. Inc.
Pfizer
Johnson & Johnson
Peptide Institute
Abbexa
Phoenix Pharmaceuticals
Creative Peptides
Outline of Major Chapters:
Chapter 1: Introduces the definition of Endogenous Peptide Substances, market overview.
Chapter 2: Global Endogenous Peptide Substances market size in revenue.
Chapter 3: Detailed analysis of Endogenous Peptide Substances company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Endogenous Peptide Substances in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.

*** レポート目次（コンテンツ）***

1 Introduction to Research & Analysis Reports
1.1 Endogenous Peptide Substances Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Endogenous Peptide Substances Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Endogenous Peptide Substances Overall Market Size
2.1 Global Endogenous Peptide Substances Market Size: 2022 VS 2029
2.2 Global Endogenous Peptide Substances Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Endogenous Peptide Substances Players in Global Market
3.2 Top Global Endogenous Peptide Substances Companies Ranked by Revenue
3.3 Global Endogenous Peptide Substances Revenue by Companies
3.4 Top 3 and Top 5 Endogenous Peptide Substances Companies in Global Market, by Revenue in 2022
3.5 Global Companies Endogenous Peptide Substances Product Type
3.6 Tier 1, Tier 2 and Tier 3 Endogenous Peptide Substances Players in Global Market
3.6.1 List of Global Tier 1 Endogenous Peptide Substances Companies
3.6.2 List of Global Tier 2 and Tier 3 Endogenous Peptide Substances Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Endogenous Peptide Substances Market Size Markets, 2022 & 2029
4.1.2 Neuropeptides
4.1.3 Hormones
4.1.4 Cytokines
4.1.5 Peptide Hormones
4.1.6 Bioactive Peptides
4.2 By Type – Global Endogenous Peptide Substances Revenue & Forecasts
4.2.1 By Type – Global Endogenous Peptide Substances Revenue, 2018-2023
4.2.2 By Type – Global Endogenous Peptide Substances Revenue, 2024-2029
4.2.3 By Type – Global Endogenous Peptide Substances Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Endogenous Peptide Substances Market Size, 2022 & 2029
5.1.2 Research
5.1.3 Medicine
5.1.4 Others
5.2 By Application – Global Endogenous Peptide Substances Revenue & Forecasts
5.2.1 By Application – Global Endogenous Peptide Substances Revenue, 2018-2023
5.2.2 By Application – Global Endogenous Peptide Substances Revenue, 2024-2029
5.2.3 By Application – Global Endogenous Peptide Substances Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Endogenous Peptide Substances Market Size, 2022 & 2029
6.2 By Region – Global Endogenous Peptide Substances Revenue & Forecasts
6.2.1 By Region – Global Endogenous Peptide Substances Revenue, 2018-2023
6.2.2 By Region – Global Endogenous Peptide Substances Revenue, 2024-2029
6.2.3 By Region – Global Endogenous Peptide Substances Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Endogenous Peptide Substances Revenue, 2018-2029
6.3.2 US Endogenous Peptide Substances Market Size, 2018-2029
6.3.3 Canada Endogenous Peptide Substances Market Size, 2018-2029
6.3.4 Mexico Endogenous Peptide Substances Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Endogenous Peptide Substances Revenue, 2018-2029
6.4.2 Germany Endogenous Peptide Substances Market Size, 2018-2029
6.4.3 France Endogenous Peptide Substances Market Size, 2018-2029
6.4.4 U.K. Endogenous Peptide Substances Market Size, 2018-2029
6.4.5 Italy Endogenous Peptide Substances Market Size, 2018-2029
6.4.6 Russia Endogenous Peptide Substances Market Size, 2018-2029
6.4.7 Nordic Countries Endogenous Peptide Substances Market Size, 2018-2029
6.4.8 Benelux Endogenous Peptide Substances Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Endogenous Peptide Substances Revenue, 2018-2029
6.5.2 China Endogenous Peptide Substances Market Size, 2018-2029
6.5.3 Japan Endogenous Peptide Substances Market Size, 2018-2029
6.5.4 South Korea Endogenous Peptide Substances Market Size, 2018-2029
6.5.5 Southeast Asia Endogenous Peptide Substances Market Size, 2018-2029
6.5.6 India Endogenous Peptide Substances Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Endogenous Peptide Substances Revenue, 2018-2029
6.6.2 Brazil Endogenous Peptide Substances Market Size, 2018-2029
6.6.3 Argentina Endogenous Peptide Substances Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Endogenous Peptide Substances Revenue, 2018-2029
6.7.2 Turkey Endogenous Peptide Substances Market Size, 2018-2029
6.7.3 Israel Endogenous Peptide Substances Market Size, 2018-2029
6.7.4 Saudi Arabia Endogenous Peptide Substances Market Size, 2018-2029
6.7.5 UAE Endogenous Peptide Substances Market Size, 2018-2029
7 Endogenous Peptide Substances Companies Profiles
7.1 Assertio Therapeutics Inc.
7.1.1 Assertio Therapeutics Inc. Company Summary
7.1.2 Assertio Therapeutics Inc. Business Overview
7.1.3 Assertio Therapeutics Inc. Endogenous Peptide Substances Major Product Offerings
7.1.4 Assertio Therapeutics Inc. Endogenous Peptide Substances Revenue in Global Market (2018-2023)
7.1.5 Assertio Therapeutics Inc. Key News & Latest Developments
7.2 Cipher Pharmaceuticals Inc.
7.2.1 Cipher Pharmaceuticals Inc. Company Summary
7.2.2 Cipher Pharmaceuticals Inc. Business Overview
7.2.3 Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Major Product Offerings
7.2.4 Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Revenue in Global Market (2018-2023)
7.2.5 Cipher Pharmaceuticals Inc. Key News & Latest Developments
7.3 Endo International Plc
7.3.1 Endo International Plc Company Summary
7.3.2 Endo International Plc Business Overview
7.3.3 Endo International Plc Endogenous Peptide Substances Major Product Offerings
7.3.4 Endo International Plc Endogenous Peptide Substances Revenue in Global Market (2018-2023)
7.3.5 Endo International Plc Key News & Latest Developments
7.4 Biosynth Carbosynth
7.4.1 Biosynth Carbosynth Company Summary
7.4.2 Biosynth Carbosynth Business Overview
7.4.3 Biosynth Carbosynth Endogenous Peptide Substances Major Product Offerings
7.4.4 Biosynth Carbosynth Endogenous Peptide Substances Revenue in Global Market (2018-2023)
7.4.5 Biosynth Carbosynth Key News & Latest Developments
7.5 Lannett Co. Inc.
7.5.1 Lannett Co. Inc. Company Summary
7.5.2 Lannett Co. Inc. Business Overview
7.5.3 Lannett Co. Inc. Endogenous Peptide Substances Major Product Offerings
7.5.4 Lannett Co. Inc. Endogenous Peptide Substances Revenue in Global Market (2018-2023)
7.5.5 Lannett Co. Inc. Key News & Latest Developments
7.6 Pfizer
7.6.1 Pfizer Company Summary
7.6.2 Pfizer Business Overview
7.6.3 Pfizer Endogenous Peptide Substances Major Product Offerings
7.6.4 Pfizer Endogenous Peptide Substances Revenue in Global Market (2018-2023)
7.6.5 Pfizer Key News & Latest Developments
7.7 Johnson & Johnson
7.7.1 Johnson & Johnson Company Summary
7.7.2 Johnson & Johnson Business Overview
7.7.3 Johnson & Johnson Endogenous Peptide Substances Major Product Offerings
7.7.4 Johnson & Johnson Endogenous Peptide Substances Revenue in Global Market (2018-2023)
7.7.5 Johnson & Johnson Key News & Latest Developments
7.8 Peptide Institute
7.8.1 Peptide Institute Company Summary
7.8.2 Peptide Institute Business Overview
7.8.3 Peptide Institute Endogenous Peptide Substances Major Product Offerings
7.8.4 Peptide Institute Endogenous Peptide Substances Revenue in Global Market (2018-2023)
7.8.5 Peptide Institute Key News & Latest Developments
7.9 Abbexa
7.9.1 Abbexa Company Summary
7.9.2 Abbexa Business Overview
7.9.3 Abbexa Endogenous Peptide Substances Major Product Offerings
7.9.4 Abbexa Endogenous Peptide Substances Revenue in Global Market (2018-2023)
7.9.5 Abbexa Key News & Latest Developments
7.10 Phoenix Pharmaceuticals
7.10.1 Phoenix Pharmaceuticals Company Summary
7.10.2 Phoenix Pharmaceuticals Business Overview
7.10.3 Phoenix Pharmaceuticals Endogenous Peptide Substances Major Product Offerings
7.10.4 Phoenix Pharmaceuticals Endogenous Peptide Substances Revenue in Global Market (2018-2023)
7.10.5 Phoenix Pharmaceuticals Key News & Latest Developments
7.11 Creative Peptides
7.11.1 Creative Peptides Company Summary
7.11.2 Creative Peptides Business Overview
7.11.3 Creative Peptides Endogenous Peptide Substances Major Product Offerings
7.11.4 Creative Peptides Endogenous Peptide Substances Revenue in Global Market (2018-2023)
7.11.5 Creative Peptides Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer

List of Tables
Table 1. Endogenous Peptide Substances Market Opportunities & Trends in Global Market
Table 2. Endogenous Peptide Substances Market Drivers in Global Market
Table 3. Endogenous Peptide Substances Market Restraints in Global Market
Table 4. Key Players of Endogenous Peptide Substances in Global Market
Table 5. Top Endogenous Peptide Substances Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Endogenous Peptide Substances Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Endogenous Peptide Substances Revenue Share by Companies, 2018-2023
Table 8. Global Companies Endogenous Peptide Substances Product Type
Table 9. List of Global Tier 1 Endogenous Peptide Substances Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Endogenous Peptide Substances Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Endogenous Peptide Substances Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Endogenous Peptide Substances Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Endogenous Peptide Substances Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global Endogenous Peptide Substances Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Endogenous Peptide Substances Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Endogenous Peptide Substances Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global Endogenous Peptide Substances Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Endogenous Peptide Substances Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Endogenous Peptide Substances Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Endogenous Peptide Substances Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Endogenous Peptide Substances Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Endogenous Peptide Substances Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Endogenous Peptide Substances Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Endogenous Peptide Substances Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Endogenous Peptide Substances Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Endogenous Peptide Substances Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Endogenous Peptide Substances Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Endogenous Peptide Substances Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Endogenous Peptide Substances Revenue, (US$, Mn), 2024-2029
Table 30. Assertio Therapeutics Inc. Company Summary
Table 31. Assertio Therapeutics Inc. Endogenous Peptide Substances Product Offerings
Table 32. Assertio Therapeutics Inc. Endogenous Peptide Substances Revenue (US$, Mn) & (2018-2023)
Table 33. Assertio Therapeutics Inc. Key News & Latest Developments
Table 34. Cipher Pharmaceuticals Inc. Company Summary
Table 35. Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Product Offerings
Table 36. Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Revenue (US$, Mn) & (2018-2023)
Table 37. Cipher Pharmaceuticals Inc. Key News & Latest Developments
Table 38. Endo International Plc Company Summary
Table 39. Endo International Plc Endogenous Peptide Substances Product Offerings
Table 40. Endo International Plc Endogenous Peptide Substances Revenue (US$, Mn) & (2018-2023)
Table 41. Endo International Plc Key News & Latest Developments
Table 42. Biosynth Carbosynth Company Summary
Table 43. Biosynth Carbosynth Endogenous Peptide Substances Product Offerings
Table 44. Biosynth Carbosynth Endogenous Peptide Substances Revenue (US$, Mn) & (2018-2023)
Table 45. Biosynth Carbosynth Key News & Latest Developments
Table 46. Lannett Co. Inc. Company Summary
Table 47. Lannett Co. Inc. Endogenous Peptide Substances Product Offerings
Table 48. Lannett Co. Inc. Endogenous Peptide Substances Revenue (US$, Mn) & (2018-2023)
Table 49. Lannett Co. Inc. Key News & Latest Developments
Table 50. Pfizer Company Summary
Table 51. Pfizer Endogenous Peptide Substances Product Offerings
Table 52. Pfizer Endogenous Peptide Substances Revenue (US$, Mn) & (2018-2023)
Table 53. Pfizer Key News & Latest Developments
Table 54. Johnson & Johnson Company Summary
Table 55. Johnson & Johnson Endogenous Peptide Substances Product Offerings
Table 56. Johnson & Johnson Endogenous Peptide Substances Revenue (US$, Mn) & (2018-2023)
Table 57. Johnson & Johnson Key News & Latest Developments
Table 58. Peptide Institute Company Summary
Table 59. Peptide Institute Endogenous Peptide Substances Product Offerings
Table 60. Peptide Institute Endogenous Peptide Substances Revenue (US$, Mn) & (2018-2023)
Table 61. Peptide Institute Key News & Latest Developments
Table 62. Abbexa Company Summary
Table 63. Abbexa Endogenous Peptide Substances Product Offerings
Table 64. Abbexa Endogenous Peptide Substances Revenue (US$, Mn) & (2018-2023)
Table 65. Abbexa Key News & Latest Developments
Table 66. Phoenix Pharmaceuticals Company Summary
Table 67. Phoenix Pharmaceuticals Endogenous Peptide Substances Product Offerings
Table 68. Phoenix Pharmaceuticals Endogenous Peptide Substances Revenue (US$, Mn) & (2018-2023)
Table 69. Phoenix Pharmaceuticals Key News & Latest Developments
Table 70. Creative Peptides Company Summary
Table 71. Creative Peptides Endogenous Peptide Substances Product Offerings
Table 72. Creative Peptides Endogenous Peptide Substances Revenue (US$, Mn) & (2018-2023)
Table 73. Creative Peptides Key News & Latest Developments
List of Figures
Figure 1. Endogenous Peptide Substances Segment by Type in 2022
Figure 2. Endogenous Peptide Substances Segment by Application in 2022
Figure 3. Global Endogenous Peptide Substances Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Endogenous Peptide Substances Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Endogenous Peptide Substances Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Endogenous Peptide Substances Revenue in 2022
Figure 8. By Type - Global Endogenous Peptide Substances Revenue Market Share, 2018-2029
Figure 9. By Application - Global Endogenous Peptide Substances Revenue Market Share, 2018-2029
Figure 10. By Type - Global Endogenous Peptide Substances Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Endogenous Peptide Substances Revenue Market Share, 2018-2029
Figure 12. By Application - Global Endogenous Peptide Substances Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Endogenous Peptide Substances Revenue Market Share, 2018-2029
Figure 14. By Region - Global Endogenous Peptide Substances Revenue Market Share, 2018-2029
Figure 15. By Country - North America Endogenous Peptide Substances Revenue Market Share, 2018-2029
Figure 16. US Endogenous Peptide Substances Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Endogenous Peptide Substances Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Endogenous Peptide Substances Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Endogenous Peptide Substances Revenue Market Share, 2018-2029
Figure 20. Germany Endogenous Peptide Substances Revenue, (US$, Mn), 2018-2029
Figure 21. France Endogenous Peptide Substances Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Endogenous Peptide Substances Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Endogenous Peptide Substances Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Endogenous Peptide Substances Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Endogenous Peptide Substances Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Endogenous Peptide Substances Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Endogenous Peptide Substances Revenue Market Share, 2018-2029
Figure 28. China Endogenous Peptide Substances Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Endogenous Peptide Substances Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Endogenous Peptide Substances Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Endogenous Peptide Substances Revenue, (US$, Mn), 2018-2029
Figure 32. India Endogenous Peptide Substances Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Endogenous Peptide Substances Revenue Market Share, 2018-2029
Figure 34. Brazil Endogenous Peptide Substances Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Endogenous Peptide Substances Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Endogenous Peptide Substances Revenue Market Share, 2018-2029
Figure 37. Turkey Endogenous Peptide Substances Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Endogenous Peptide Substances Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Endogenous Peptide Substances Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Endogenous Peptide Substances Revenue, (US$, Mn), 2018-2029
Figure 41. Assertio Therapeutics Inc. Endogenous Peptide Substances Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Cipher Pharmaceuticals Inc. Endogenous Peptide Substances Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. Endo International Plc Endogenous Peptide Substances Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Biosynth Carbosynth Endogenous Peptide Substances Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Lannett Co. Inc. Endogenous Peptide Substances Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Pfizer Endogenous Peptide Substances Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Johnson & Johnson Endogenous Peptide Substances Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. Peptide Institute Endogenous Peptide Substances Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Abbexa Endogenous Peptide Substances Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Phoenix Pharmaceuticals Endogenous Peptide Substances Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Creative Peptides Endogenous Peptide Substances Revenue Year Over Year Growth (US$, Mn) & (2018-2023)



*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/
※関連調査資料
  • 子宮内避妊具（IUCD）のグローバル市場展望 2023年-2029年：非ホルモン、ホルモン、不活性
  • 原発性免疫不全薬のグローバル市場展望 2023年-2029年：サイトカイン、抗サイトカイン抗体、シグナル分子阻害剤
  • 動物用医薬品調剤のグローバル市場展望 2023年-2029年：抗感染症薬、ホルモン＆代替薬、抗炎症薬、その他
  • 細胞栄養補助食品のグローバル市場展望 2023年-2029年：抗生物質、L-グルタミン&グルタマックスサプリメント、細胞培養緩衝液、成長因子&サイトカイン、ウシ血清アルブミン（BSE）、その他
  • 長鎖ペプチド医薬品のグローバル市場展望 2023年-2029年：ホルモンペプチド製剤、免疫調節ペプチド製剤、血管作動性ペプチド製剤、その他
    • ※注目の調査資料
     ※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
    ※当市場調査資料(MMG23DC12333 )"内因性ペプチド物質のグローバル市場展望 2023年-2029年：神経ペプチド、ホルモン、サイトカイン、ペプチドホルモン、生理活性ペプチド" (英文：Endogenous Peptide Substances Market, Global Outlook and Forecast 2023-2029)はMarket Monitor Global社が調査・発行しており、H&Iグローバルリサーチが販売します。

    ◆H&Iグローバルリサーチのお客様（例）◆


    ※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
    ※無料翻訳ツールをご利用いただけます。翻訳可能なPDF納品ファイルが対象です。ご利用を希望されるお客様はご注文の時にその旨をお申し出ください。